Annexon, Inc. (ANNX)

Annexon's stock price has fluctuated, declining 58.65% from October 22, 2024, to October 21, 2025, but recently gaining 10.28% on October 27, 2025. Key events include narrowing its loss in fiscal Q2, completing enrollment in the Phase 3 ARCHER II trial, an insider purchase of shares, being dropped from the Russell 2500 Growth Index, appointing Dr. Lloyd Clark as Senior VP, and outlining its 2025 outlook with milestones such as a BLA submission for ANX005, completion of Phase 3 ARCHER II trial enrollment for ANX007, and clinical proof-of-concept data for ANX1502.

As a clinical-stage biopharmaceutical company, Annexon, Inc. does not currently have commercialized products or services that would exhibit demand seasonality. The company's revenue generation is primarily anticipated through the successful commercialization of its product candidates, partnerships, and potential licensing agreements, which are not subject to seasonal demand fluctuations.

Annexon, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for complement-mediated diseases by inhibiting C1q. Their pipeline includes ANX005 (tanruprubart) in Phase 3 trials for Guillain-Barré Syndrome (GBS) and Phase 2 trials for Huntington's disease and amyotrophic lateral sclerosis, ANX007 (vonaprument) in Phase 3 for geographic atrophy (GA), ANX1502 in Phase 1 for autoimmune indications, and ANX009 in Phase 1 for lupus nephritis.

Annexon, Inc. is headquartered in Brisbane and South San Francisco, California, with clinical development programs in North America, Europe, and Asia.

Annexon's brand reputation is tied to its clinical trial progress and analyst sentiment. MarketBeat ranked Annexon higher than 40% of companies in the medical sector. Analyst ratings reflect a mixed but generally positive outlook, with a consensus "Hold" rating and an average twelve-month stock price forecast suggesting a potential upside. However, there was a mention of "Annexon: Unforced Error Sullies Prospects," and concerns about financial risks have been noted.

Annexon, Inc. has a diverse ownership structure, with institutional investors holding approximately 75.8% of the company's outstanding shares. Major institutional owners include Fmr Llc, BlackRock, Inc., Vanguard Group Inc., Bain Capital Life Sciences Investors, LLC, and Redmile Group, LLC. Bain Capital Life Sciences Investors LLC is the largest individual shareholder, holding 10.10% of the company.